50 Participants Needed

Fulvestrant +/− Ganetespib for Breast Cancer

Recruiting at 4 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot be on other treatments intended to treat your cancer while participating. You must also be at least 2 weeks from your last chemotherapy or radiotherapy.

What data supports the effectiveness of the drug Fulvestrant for breast cancer?

Fulvestrant has been shown to be effective in treating advanced breast cancer in postmenopausal women, with studies indicating it is at least as effective as other treatments like anastrozole. It has demonstrated a clinical benefit rate of 29.9% in heavily pretreated patients, showing its potential as a valuable option for those who have progressed on prior therapies.12345

Is Fulvestrant safe for use in humans?

Fulvestrant (Faslodex) has been generally well tolerated in clinical studies for advanced breast cancer, with only a small percentage of patients discontinuing due to side effects.13678

How is the drug Fulvestrant unique for treating breast cancer?

Fulvestrant is unique because it is an estrogen receptor antagonist that works by blocking and degrading the estrogen receptor without any stimulating effects, making it effective for postmenopausal women with advanced breast cancer who have not responded to other hormone therapies.12368

What is the purpose of this trial?

Ganetespib is a drug that may stop cancer cells from growing. This drug has been used in other research studies and laboratory experiments. It has also been studied in phase I trials, where the appropriate dosing has been determined. Ganetespib is considered an "HSP90 inhibitor". By blocking HSP90, ganetespib is thought to reduce the ability of cancer cells to become resistant to treatment.Fulvestrant is a hormonal therapy that works by attaching to estrogen receptors. In doing so, it can block the effect of estrogen on cancer cells. In addition, fulvestrant causes a decrease in the number of estrogen receptors. Fulvestrant is a drug that is approved by the FDA for treatment of metastatic, hormone receptor positive breast cancer, based upon the results of phase III clinical trials.In the laboratory, adding ganetespib to fulvestrant appears to improve its effectiveness. It is not known whether this is true in humans. In this research study, we are evaluating the effect of the addition of ganetespib to fulvestrant in participants with hormone receptor-positive, metastatic breast cancer.

Research Team

NU

Nancy U Lin, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

This trial is for individuals with hormone receptor-positive, metastatic breast cancer that's HER2 negative. Participants can have had one prior chemotherapy treatment and must have measurable disease. They should be in good physical condition (ECOG status of 0 or 1) and not currently pregnant or breastfeeding. Those who've previously used fulvestrant or HSP90 inhibitors, have untreated brain metastases, other recent cancers, or severe illnesses are excluded.

Inclusion Criteria

My cancer is not HER2 positive.
You need to have a way to measure the disease for the study.
My breast cancer has not responded to hormone therapy.
See 9 more

Exclusion Criteria

Pregnant or breastfeeding
You are at risk of a severe medical issue, according to the doctor in charge of your treatment.
You have had allergic reactions to drugs similar to fulvestrant or ganetespib.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Fulvestrant with or without Ganetespib. Fulvestrant is administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; Ganetespib is administered intravenously on days 1, 8, and 15 of each 28-day cycle.

38 months
Visits every cycle (28 days)

Follow-up

Participants are monitored for safety and effectiveness after treatment. Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles thereafter. Participants were followed for survival up to 4 years from treatment end.

4 years
Every 3 months

Treatment Details

Interventions

  • Fulvestrant
  • Ganetespib
Trial Overview The study is testing the effectiveness of combining Ganetespib, an HSP90 inhibitor thought to prevent cancer cell resistance, with Fulvestrant, a hormonal therapy approved by the FDA for certain breast cancers. The goal is to see if adding Ganetespib improves outcomes compared to using Fulvestrant alone.
Participant Groups
2Treatment groups
Active Control
Group I: Arm B - Fulvestrant+GanetespibActive Control2 Interventions
Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression.
Group II: ARM A - FulvestrantActive Control1 Intervention
Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.

Fulvestrant is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Faslodex for:
  • Hormone receptor-positive metastatic breast cancer
  • Locally advanced breast cancer
🇺🇸
Approved in United States as Faslodex for:
  • Hormone receptor-positive metastatic breast cancer
  • Locally advanced breast cancer
🇨🇦
Approved in Canada as Faslodex for:
  • Hormone receptor-positive metastatic breast cancer
  • Locally advanced breast cancer
🇯🇵
Approved in Japan as Faslodex for:
  • Hormone receptor-positive metastatic breast cancer
  • Locally advanced breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

Findings from Research

In a study of 54 postmenopausal women with metastatic breast cancer, fulvestrant demonstrated clinical benefit in 38.9% of patients, with a median time to progression of 6.4 months, indicating its efficacy even after multiple prior treatments.
Fulvestrant was well tolerated, with no severe toxicities (grade 3/4) reported, suggesting it is a safe option for patients with advanced breast cancer who have limited treatment options.
Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.Mlineritsch, B., Psenak, O., Mayer, P., et al.[2018]
In a study involving 451 postmenopausal women with advanced breast cancer, fulvestrant was found to be as effective as anastrozole in terms of time to progression, with median times of 5.5 months for fulvestrant and 5.1 months for anastrozole.
Both treatments were well tolerated, with low withdrawal rates due to adverse events (3.2% for fulvestrant and 1.3% for anastrozole), indicating that fulvestrant is a safe and effective option for patients who have progressed on prior endocrine therapy.
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.Howell, A., Robertson, JF., Quaresma Albano, J., et al.[2022]
In a study of 402 postmenopausal women with advanced breast cancer receiving fulvestrant through a Compassionate Use Program, 29.9% experienced clinical benefits, including partial responses and stable disease for over 6 months.
Fulvestrant was well tolerated, with only 1.5% of patients discontinuing treatment due to adverse events, indicating its safety and potential as an effective option for patients who have not responded to previous therapies.
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.Neven, P., Paridaens, R., Pelgrims, G., et al.[2018]

References

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. [2018]
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. [2022]
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. [2018]
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. [2022]
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. [2018]
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. [2022]
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. [2018]
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security